Spero Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-9.6M | $-7.2M | $-7.4M | $-1.7M | $-13.9M | $-17.1M | $-17.9M | $-12.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | $0 |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $822.0K | $1.1M | $1.0M | $714.0K | $1.6M | $2.2M | $2.1M | $2.0M |
| Net Cash from Operating Activities | $-5.4M | $15.9M | $17.4M | $-17.7M | $-4.0M | $12.8M | $-18.7M | $5.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | — | — | — | — | — | — |
| Net Change in Cash | — | $15.9M | — | — | $-4.0M | — | — | $5.9M |
| Free Cash Flow | — | — | — | — | — | — | — | — |